Table 1 Details of normalization of coagulating status
State | Normalization of coagulating status |
|---|---|
During anticoagulated and antiplatelet therapy | Discontinue the medication Reversals such as vitamin K, idarucizumab, and PCC |
Platelet count > 5 × 109/l | Platelet transfusion |
Clauss fibrinogen level ≤ 1.5 g/l | Administration of FFP |
Presence of hemophilia | aPCC and recombinant factor VIIa |